Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CCR3 | P51677 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803450 | 0.91 | HRH4 (0.33) | EPHX2HRH4CCR5 | |
| SCHEMBL1803156 | 0.79 | MAPK1 (0.51) | MEN1KMT2A | |
| SCHEMBL1798741 | 0.78 | HSD11B1 (0.40) | CCR5KMT2A | |
| SCHEMBL1802777 | 0.78 | — | — | |
| SCHEMBL1802265 | 0.76 | KMT2A (0.55) | MEN1KMT2A | |
| SCHEMBL3915996 | 0.76 | HDAC8 (0.36) | MEN1KMT2A | |
| SCHEMBL1800401 | 0.75 | CYP1A2 (0.49) | — | |
| SCHEMBL1799346 | 0.75 | GAA (0.37) | EPHX2CCR5KMT2A | |
| SCHEMBL1808204 | 0.73 | AVPR1A (0.46) | CCR5MEN1KMT2A | |
| SCHEMBL1800370 | 0.73 | HPGD (0.48) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | claimed |
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | claimed |
| WO-2005095402-A9 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2009-06-11 | — | — | WO | claimed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | claimed |
| EP-1730147-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Grünenthal GmbH (DE) | 2006-12-13 | — | — | EP | claimed |
| WO-2005095402-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Grünenthal GmbH (DE) | 2005-10-13 | — | — | WO | claimed |
| US-7951815-B2 | Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | disclosed |
| EP-1730147-B1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | GRUENENTHAL GMBH (DE) | 2010-02-03 | — | — | EP | disclosed |
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
| EP-1730147-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Grünenthal GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095402-A1 | SUBSTITUTED 1,4,8-TRIAZASPIRO[4.5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY | Grünenthal GmbH (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015784-A1 | Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds | SI, SSTR4, SLC10A2 | EPHX2 4594/4885HRH4 1299/4885CCR5 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.